<DOC>
	<DOCNO>NCT00519857</DOCNO>
	<brief_summary>Tibolone 1.25 mg effective treatment prevention osteoporosis expect effective preventing fracture osteoporotic woman . Tibolone could acceptable long-term use , particular since induce regular withdrawal bleed . The objective trial compare placebo tibolone , steroid tissue specific activity , prevention spinal fracture woman meet WHO criteria osteoporosis asymptomatic vertebral fracture .</brief_summary>
	<brief_title>Trial Evaluate Tibolone Treatment Osteoporosis ( P06468 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Tibolone</mesh_term>
	<criteria>Voluntary write informed consent , willing able make reasonable effort observe clinical trial requirement enrol Subjects postmenopausal ( naturally surgically ) woman , 60 85 year age ( inclusive ) entry Screening BMD total hip and/or spine equal low 2.5 SD Tscore subject without asymptomatic fracture equal low 2.0 SD Tscore subject asymptomatic fracture Subjects Body Mass Index ( BMI ) = 34 kg/m^2 . Subjects follow condition enrol trial : Recent acute vertebral fracture ( diagnose within last year ) document spinal radiograph require medication osteoporosis treatment , judgment investigator More two prevalent asymptomatic vertebral fracture baseline Screening BMD total hip spine low 4 SD Tscore Unsuitable anatomy spinal radiograph ( lumbar thoracic vertebra ) e.g. , excessive scoliosis Not ambulatory History presence malignancy within past five year except nonmelanoma skin cancer . Subjects ever history ovarian cancer estrogen dependent tumor particularly breast endometrial cancer exclude Trans vaginal ultrasound ( TVUS ) endometrial double wall thickness &gt; 4 mm Unexplained abnormal vaginal bleeding past year prior screen Abnormal cervical Papanicolaou ( Pap ) smear ( include low grade squamous intraepithelial lesion ( LSIL ) , high grade squamous intraepithelial lesion ( HSIL ) , atypical squamous cell undetermined significance ( ASCUS ) , atypical gland undetermined significance ( AGCUS ) ) Mammography find suspicious malignancy Bone disease osteoporosis Paget 's disease , osteomalacia , hyperparathyroidism , bone metastasis Treatment anabolic steroid , calcitonin , raloxifene , tamoxifen , calcitriol within last six month prior screen BMD spinal Xray measurement . Treatment systemic estrogen and/or progestin within last three month prior screen BMD spinal Xray measurement ( occasional use estriol contain vaginal cream allow ) Treatment bisphosphonates one month within last year Ever use estrogen and/or progestin contain implant</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>